Sign in
Taking people in FinlandPhase 4

Blood-thinning medicine to prevent clots during pancreatic cancer treatment

Tests extra clot prevention in people with pancreatic cancer receiving pre-surgery treatment.

Key facts

Who runs it
HUS-Yhtymae
Where
Helsinki, Oulu, Tampere, and Turku, FinlandSee the 4 sites
Registry title
Prevention of thromboembolism during pancreatic cancer treatments - link to prognosis and relapse of the disease.
Status
Recruiting
Phase
Phase 4
People taking part
214 people, planned
Started
27 Nov 2024
Expected to end
1 Jan 2035
Type of study
Interventional
Record updated
27 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pancreatic cancer who are about to start treatment before surgery (neoadjuvant treatment). It studies blood-clot prevention during that treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Pancreatic cancer, with treatment before surgery (neoadjuvant treatment) being planned.
Earlier treatment
Must not already be taking blood-thinning (anticoagulant) medicine.

Main reasons for not taking part

  • Cannot use tinzaparin (a blood thinner) for medical reasons
  • Already taking blood-thinning (anticoagulant) medicine
  • Another active cancer in the past five years
  • Severe kidney failure
  • Tendency to bleed

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • An adult pancreatic cancer patient for whom neoadjuvant treatments are being planned due to pancreatic cancer

Who cannot take part

  • The study excludes patients, if they have contraindications for using tinzaparin, are already on anticoagulant medication, have had any other active cancer in the past five years or have severe kidney failure or bleeding tendencies

Where in Finland

  • HUS-YhtymaeHelsinki, FinlandTaking people
  • Oulu University HospitalOulu, FinlandTaking people
  • Tampere University HospitalTampere, FinlandTaking people
  • Turku University HospitalTurku, FinlandTaking people

About the trial

What the trial wants to find out

Neoadjuvant-treated pancreatic cancer patients are at increased risk of thrombosis. Our aim is to investigate the impact of thromboprophylaxis administered during neoadjuvant treatments on the risk of vascular events and survival prognosis in pancreatic cancer patients in a randomized prospective study.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Thrombosis prophylaxis and coagulation activation during neoadjuvant treatment in pancreatic cancer - Association to prognosis and recurrence.
Plain-language title
Blood-thinning medicine to prevent clots during pancreatic cancer treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
27 November 2024